Nephrocare Health Services Limited IPO

₹14,720 Min Investment

Issue Opening Date
10 December 2025
Issue Closing Date
12 December 2025
Price Band
Rs. 438 to Rs.460 per share
Lot Size
32 Shares
IPO Fact Sheet
Download Now
Nephrocare Health Services Limited IPO ClosedOpen

₹14,720

Min. investment
Invest Now

Snapshot

NephroPlus is India’s largest dialysis service provider, operating a nationwide network of dialysis centers under a standardized, patient-centric model. Founded to make high-quality and affordable renal care accessible, the company offers dialysis treatments, home hemodialysis solutions, and comprehensive kidney-care programs. NephroPlus partners with hospitals, clinics, and government institutions to expand its reach, while maintaining strict clinical protocols and technological support systems. With strong brand recognition, a scalable operational model, and long-term demand driven by rising chronic kidney disease cases, NephroPlus is positioned as a leading player in India’s growing dialysis services market.

Company Vision

NephroPlus envisions becoming the most trusted and accessible dialysis care provider in India and international markets by delivering consistent, high-quality, and patient-centric renal services. The company aims to transform dialysis care through standardized clinical protocols, advanced technology, and continuous innovation. Its vision focuses on expanding access to affordable treatment, empowering patients to lead healthier and more independent lives, and building long-term partnerships with hospitals and government institutions. NephroPlus aspires to set global benchmarks in safety, service quality, and operational excellence, creating a reliable ecosystem for chronic kidney disease management.

Growth Prospects

NephroPlus has strong growth prospects driven by rising demand for dialysis services in India, fueled by increasing chronic kidney disease cases and limited existing infrastructure. The company is well positioned to expand through its proven Hub & Spoke and PPP partnership models, allowing rapid scaling across states and hospitals. Its standardized clinical protocols, focus on affordability, and strong brand recognition further enhance competitiveness. International expansion, home hemodialysis solutions, and technology-enabled patient monitoring offer additional growth avenues. With long-term government collaborations and operational excellence, NephroPlus is poised to strengthen its leadership in the Indian and global dialysis care market.

Risk

NephroPlus faces several risks that could affect its operations and growth. The company is exposed to healthcare regulatory changes, clinical compliance requirements, and strict quality standards across multiple states, and any lapse can result in penalties or reputational damage. Its business depends heavily on long-term contracts with hospitals and government bodies, making it vulnerable to contract non-renewals or pricing pressure. High dependence on skilled technicians and medical staff also poses operational challenges. Increasing competition in dialysis services, rising costs of medical consumables, and potential litigation related to patient outcomes further add to business uncertainty for NephroPlus.

Nephrocare Health Services Limited Details

Issue Opening Date 10 December 2025
Issue Closing Date 12 December 2025
Price Band Rs. 438 to Rs.460 per share
Bid Lot 32 Shares
Face value Rs.2 per share
Issue Size 1,89,35,819 share (aggregating up to Rs.871.05 Cr)
Fresh Issue 76,82,717 share (aggregating up to Rs.353.40 Cr)
Offer for Sale 1,12,53,102 share (aggregating up to Rs.517.64 Cr)
Registrar Kfin Technologies Ltd.

Nephrocare Health Services Limited Timeline (Tentative Schedule)

IPO Open Date 10 December 2025
IPO Close Date 12 December 2025
Tentative Allotment Friday, December 15, 2025
Initiation of Refunds Monday, December 16, 2025
Credit of Shares to Demat Monday, December 16, 2025
Tentative Listing Date Tuesday, December 17, 2025
Cut- off time for UPI mantate Confirmation 5 PM on Thursday, December 12, 2025

Nephrocare Health Services Limited Financial Information (Restated)

Amount in Cr. 30-Sep-25 FY2025 FY2024 FY2023
Total Assets 1,193.68 996.46 806.02 666.23
Total Revenue 483.97 769.92 574.72 443.26
Profit After Tax 14.23 67.10 35.13 -11.79
EBITDA 110.31 166.64 99.66 48.60
Net Worth 716.06 594.21 423.55 384.73
Reserves and Surplus 704.14 578.68 408.57 383.50
Total Borrowing 207.04 225.80 243.37 196.21
Nephrocare Health Services Limited IPO  Registrar

Kfin Technologies Ltd.

04067162222, 04079611000
 nephrocare.ipo@kfintech.com
https://ipostatus.kfintech.com/

Prospectus Document

Official Red Herring Prospectus (RHP)

For detailed company and issue information

SEBI Registration No: NSE Cash: INB231219636 | SEBI Registration No: NSE Derivative: INF231219636 | SEBI Registration No: BSE Cash: INB011219632 | SEBI Registration No: MCX-SX: INE261219636 | SEBI Registration No: NSE Currency: INE231219636 | SEBI Registration No: USE: INE271219631 | SEBI Registration No: CDSL: IN-DP-CDSL-3242005 | NCDEX Membership No: 00635 | MCX Membership No: 28850 | NSEL Membership No: 10650 | RBI Registration No: NBFC: N-14.03215 | IRDA Registration Number : CB-066/03 | AMFI Registration No : ARN -0032| SEBI Registration No: Merchant Banker: INM000007508

* Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing.